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Abstract
Ventilator-associated pneumonia (VAP) and hospital acquired pneumonia (HAP) strongly contribute to morbidity 
and mortality in intensive care units. Hospital acquired pneumonia (HAP) is pneumonia occurring 48 hours upon 
admission and appears not to be incubating at the time of admission. Ventilator-associated pneumonia (VAP) is a 
type of HAP developing in intubated patients after more than 48 hours upon mechanical ventilation. HAP and VAP 
are common and serious complications present in hospitalized patients. Since the diagnosis of VAP and HAP are rarely 
documented, we wanted to assess the incidence of VAP in General Surgery and Cardiac Surgery Intensive Care Units in 
2018 and analyse the patients and procedures related factors. Patients intubated and ventilated more than 96 hours 
during 2018 were included. Our findings have shown that incidence of VAP in two analysed ICUs in UH Dubrava is in 
line with VAP incidence found in literature due to successful preventive strategies and timely initiation of antimicrobial 
therapy and other adjunctive procedures.
Sažetak
Pneumonija povezana s mehaničkom ventilacijom (engl. ventilator-associated pneumonia, VAP) i pneumonija 
stečena u bolnici (engl. hospital acquired pneumonia, HAP) snažno doprinose pobolu i smrtnosti u jedinicama za 
intenzivno liječenje. Bolnička pneumonija se javlja 48 sati nakon prijema u bolnicu i čini se da za vrijeme prijema 
nema inkubacije. Pneumonija povezana s mehaničkom ventilacijom (VAP) je vrsta bolničke pneumonije koja se 
razvija kod intubiranih bolesnika nakon više od 48 sati mehaničke ventilacije. HAP i VAP predstavljaju uobičajene 
i ozbiljne komplikacije kod hospitaliziranih bolesnika. Budući se VAP i HAP dijagnoze rijetko dokumentiraju, željeli 
smo procijeniti učestalost pneumonija povezanih s mehaničkom ventilacijom u jedinicama intenzivnog liječenja 
opće i kardijalne kirurgije u 2018. godini. U analizu su uključeni bolesnici koji su intubirani i ventilirani više od 96 
sati tijekom 2018. godine. Rezultati istraživanja pokazuju da je učestalost VAP-a u dvije jedinice za intenzivno 
liječenje u Kliničkoj bolnici Dubrava u skladu s učestalošću VAP-a utvrđenom u literaturi zahvaljujući provođenju 
uspješnih preventivnih strategija i pravodobnog započinjanja antimikrobne terapije i drugih dodatnih procedura.
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Introduction
 Ventilator-associated pneumonia (VAP) and hospi-
tal acquired pneumonia (HAP) strongly contribute to 
morbidity and mortality in intensive care units. Hos-
pital acquired pneumonia (HAP) is pneumonia occur-
ring 48 hours upon admission and appears not to be 
incubating at the time of admission. Ventilator-asso-
ciated pneumonia (VAP) is a type of HAP developing 
in intubated patients after more than 48 hours upon 
mechanical ventilation.[1] HAP and VAP are common 
and serious complications present in hospitalized pa-
tients. Together, they are among the most common 
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hospital-acquired infections (HAIs), accounting for 
22% of all HAIs.[2] HAP incidence ranges from 5 to 
more than 20 cases per 1000 hospital admissions. Ac-
cording to the literature, VAP incidence is expressed 
as number of cases per 1000 ventilator-days. US epide-
miological studies report an incidence of VAP of 2-16 
episodes per 1000 ventilator-days.[3,4] The risk of VAP 
is estimated to be higher (2-3%) during the 10 days 
of mechanical ventilation.[5] However, the incidence of 
VAP seems to be decreasing, due to better preventive 
strategies. [6] The incidence is still very high in trauma 
and brain injury patients (50%).[7] Recently published 
data demonstrated that approximately 10% of the pa-
tients who required prolonged mechanical ventilation 
(greater than 21 days of mechanical ventilation for at 
least six hours per day[8] were diagnosed with VAP.[9] 
The mortality associated with VAP has been reported 
to range from 20% to 50%, but the mortality directly 
related to VAP is debated; a recent meta-analysis de-
rived from randomized VAP prevention studies esti-
mated the attributable mortality at 13%.[10] HAP and 
VAP may be caused by different pathogens and can 
be polymicrobial. The common pathogens include 
gram-negative bacilli (Escherichia coli-5,9%, Klebsiel-
la pneumoniae-10,1%, Enterobacter spp-8,16%, Pseu-
domonas aeruginosa-16,6%, Acinetobacter spp-6,6%) 
and gram-positive cocci (Staphylococcus aureus-24,1%, 
including MRSA, Streptococcus spp., as well as Entero-
coccus spp., common nosocomial bacteria, considered 
uncommon agent of airway illnesses that can be found 
among surgical and immunocompromised patients[11].
[12] The 2016 Infectious Disease Society of America/
American Thoracic society guidelines for the manage-
ment of HAP and VAP recommend a clinical diagnosis 
based upon a new lung infiltrate plus clinical evidence 
that the infiltrate is of infectious origin, which includes 
the new onset of fever, purulent sputum, leucocytosis, 
worsening of oxygenation parameters, and significant-
ly positive microbiologic tracheal or bronchoalveolar 
lavage with 105 or 104 CFU/ml.[1] There are some pre-
disposing factors specific to VAP[13], mainly endotra-
cheal intubation and mechanical ventilation[14,15]. Risk 
factors predisposing to VAP are determined in part by 
the duration of exposure to the ICU environment and 
the presence of host factors and treatment related fac-
tors that predispose to the development of VAP[16], by 
increasing the likelihood for colonization of the aero-
digestive tract with pathogenic bacteria (e.g., prior an-
tibiotic exposure, age > 60 years, chronic obstructive 
pulmonary disease) and predisposing to the aspiration 
of contaminated secretions (e.g., supine positioning, 
coma, head trauma, etc.)[16,17].
Material and Methods
 This research was conducted as a retrospective 
observational study, using data obtained from medi-
cal records. It includes data from patients treated in 
General Surgery and Cardiac Surgery Intensive Care 
Units in the University Hospital Dubrava in 2018. 
The patients who were intubated and ventilated more 
than 96 hours from BIS computer database[18] were 
screened, and the patients with positive bacterial 
growth in tracheal aspirate or bronchoalveolar lavage 
specimens were selected for further analysis (Figure 1).
 Traditional clinical criteria for pneumonia (fever or 
hypothermia, leucocytosis or leukopenia, increase in 
volume of respiratory secretions or a change in char-
acter of the secretions, a new or progressive infiltrate 
on the chest X-ray)[19] and significantly positive micro-
biologic growth of tracheal aspirate or bronchoalveo-
lar lavage specimens with 105 or 104CFU/ml to single 
out patients with VAP. The time of presentation, com-
bined with mechanical ventilation duration, was the 
key factor to distinguish between patients diagnosed 
with VAP or HAP. Patient age, sex, ASA (American 
Society of Anaesthesiologists) classification (grading 
system for preoperative health of the surgical patients 
based on 6 classes: ASA I stands for a normal healthy 
patient and ASA VI is a declared brain-dead patient 
whose organs are being removed for donor purposes) 
– figure 2, duration of mechanical ventilation, emer-
gency and brain injury patients, adjunctive pulmonary 
procedures (bronchoscopy, pleural puncture, chest 
drainage), microbiological findings, revision of anti-
biotic therapy (change or de-escalation), elapsed time 
from diagnosis to tracheotomy, mortality, CPIS (Clini-
cal Pulmonary Infection Score) and SOFA (Sequential 
Organ Failure Assessment) score were evaluated.
Results
 In analysed ICUs, 92 patients were ventilated for 
more than 96 hours during 2018. 14 patients (15%) had 
positive criteria for VAP and 19 (20%) of them were 
diagnosed with HAP. Among 14 patients diagnosed 
with VAP, mean time from the admission to the ICU 
to diagnosis was 7.9±2.3 days. Mean patient age was 
64±15 years, and most of them were males (79%). 71% 
of patients were admitted as emergencies and 43% of 
them had severe neurotrauma. According to the ASA 
classification (American Society of Anaesthesiologists) 
of perioperative risk of complication during surgery 
and anaesthesia due to patients` existing comorbidi-
ties, more than half of the patients (57%) were initially 
evaluated as ASA IV (a patient with severe systemic 
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disease that is a constant threat to life). (Figure 1) Me-
dian duration of mechanical ventilation was 11 days 
(from 3 to 82 days). Two patients required prolonged 
mechanical ventilation. Tracheotomy was performed 
in 12 patients with VAP (85%) and the mean time 
from intubation to tracheostomy was 7.7 ±3.1 days. 
Etiological agents of the VAP in our ICU are presented 
in Table 1. Gram negative pathogens were found in 11 
cases (79%) while gram positive pathogens were found 
3 in cases (21%). There was no significant difference 
in the 28-day survival depending on pathogen agent. 
An antibiotic therapy modification was required in 5 
cases (36%). Certain pulmonary invasive procedures 
indicated for diagnostic (BAL) and therapeutic (air-
way lavage and aspiration, pleural effusion) reasons in 
patients diagnosed with VAP are shown in the Table 2. 
At the time of setting the diagnosis, the median CPIS 
was 5, and the mean SOFA score was 10.1. The mor-
tality rate among the patients was 64% (median day of 
death was 14.9±11.3). There was no statistically signif-
icant difference in mortality between VAPs and HAPs 
and emergency admission did not affect mortality.
Table 1. Frequencies of pathogens
Counts % of Total
Acinetobacter baumannii 4 29 %
Pseudomonas aeruginosa 3 21 %
Enterococcus faecalis 2 14 %
Enterobacter cloacae 2 14 %
Klebsiella oxytoca 1 7 %
Staphylococcus aureus 1 7 %
Klebsiella pneumoniae 1 7 %
Table 2. Number of pulmonary invasive procedures
YES NO
bronchoscopy 6 (43%) 8(57%)
pleurocentesis 2 (14%) 12 (86%)
chest drainage 5 (36%) 9 (64%)
Figure 1 Flowchart depicting selection criteria for VAP and HAP among patients that were ventilated and intubated 
over 96h
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Discussion and Conclusion
 The aim of this study was to assess the incidence 
of VAP and HAP in the University Hospital Dubrava 
General Surgery and Cardiac Surgery Intensive Care 
Units in 2018, but our subject of interest was primarily 
VAP. Therefore, we analysed the data from VAP pa-
tients. Due to the limitations in BIS software package, 
only patients ventilated more than 96 hours were in-
cluded, and the incidence was not expressed as num-
ber of cases per 1000 ventilator-days.
 Nevertheless, upon literature search and compari-
son with published data, similar rate of VAP incidence 
was found in our centre (10-27% according to pub-
lished data)[20,21]. Several studies in the USA and UK 
found that the most common pathogens causing VAP 
are Staphylococcus aureus (24,1%) and Pseudomonas 
aeruginosa (16,6%)[12], which is different from findings 
in our centre, in which Acinetobacter baumannii was 
the most common pathogen (4 cases). In published 
studies, the crude mortality of patients with VAP is 
highly variable (10-70%) according to case mix[22-24]. 
Among the patients in our centre mortality rate was 
64%.
 It is worth noting that only surgical patients were 
analysed, and most of them were categorized as high 
risk according to the ASA classification (III and IV). 
Also, the reason for extended ventilation was not only 
respiratory failure, but also surgical complications and 
neurological status due to neurotrauma. Among 14 
VAP diagnosed patients, only two required prolonged 
mechanical ventilation. We have established that pre-
ventive strategies in our ICU are well executed and suc-
cessful, including supine patient positioning, prevent-
ing aspiration (endotracheal tube airway cuff pressure 
maintained at 20-30 cmH2O), subglottic drainage, oral 
hygiene with hexetidine, and early initiation of empiri-
cal therapy with broad-spectrum agents to which most 
of infective agents found in patients treated in UH 
Dubrava are susceptible, and in the majority of cases 
the modification was not required. Furthermore, early 
respiratory rehabilitation performed by physiothera-
pists together with spontaneous breathing trials was 
performed with goal of weaning ventilated patients 
as soon as possible. The question of early (performed 
2-14 days – mean 7 days) versus late (performed 10 
days to three weeks – mean 14 days) tracheostomy re-
mains unresolved in the medical literature.[25] Never-
theless, some evidence suggests that early tracheosto-
my may improve some short-term clinical outcomes.
[26] When compared with late tracheostomy, early tra-
cheostomy was associated with a higher likelihood of 
weaning from the ventilator, a higher likelihood of be-
ing discharged from the ICU within 28 days, a trend 
towards a lower rate of pneumonia and similar sur-
vival at one month.[26] In our centre, we prefer early 
tracheostomy (mean 7.7 ±3.1 day) and this also can 
be a part of preventive strategies. In conclusion, data 
gathered in this preliminary observational monocen-
tric study show that rates of VAP occurrence observed 
in surgical ICUs in UH Dubrava are in accordance to 
data reported from other centres. Prospective observa-
tional studies are to be performed to further assess risk 
factors and outcomes in VAP patients.
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